Mind Medicine Mindmed is a clinical stage biopharmaceutical company developing products to treat brain health disorders, with a focus on psychiatry, addiction, pain and neurology. Co.'s drug candidates include: MM-120, which is a proprietary, pharmaceutically optimized form of lysergide, and is being developed for the treatment of generalized anxiety disorder; MM-110, which is its proprietary form of 18-methoxycoronaridine, a congener of ibogaine, that is being developed for the treatment of opioid withdrawal; and MM-402, which is its proprietary form of the R-enantiomer of 3,4-methylenedioxymethamphetamine, that is developed for the treatment of main symptoms of autism spectrum disorder. The MNMD YTD return is shown above.
The YTD Return on the MNMD YTD return page and across the coverage universe of our site,
is a measure of the total return for a given investment year-to-date for the current calendar year
(up to the end of prior trading session). Arguably, choosing the current calendar year for a measurement
period is on the one hand completely arbitrary, but on the other hand a year-to-date look can be extremely
useful in the context of our country's tax system which taxes gains and income on a calendar year basis.
Thus, researching Year-To-Date Returns is good practice for investors — whether MNMD YTD return or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's YTD return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the MNMD YTD return calculation (with any dividends reinvested as applicable), and to provide a
coverage universe of many stocks and ETFs to be able to compare YTD returns.
|